Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HI-1-164
- Development stage
- Discontinued
- Lead developer
- Bioxyne
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
HI-1-164 is an oral, inactivated (killed) whole-cell bacterial vaccine/immunotherapy derived from nontypeable *Haemophilus influenzae* (NTHi) strain 164. Developed by the Australian company Hunter Immunology, it was designed to prevent acute bronchitis and respiratory exacerbations in patients with chronic obstructive pulmonary disease (COPD) and other mild-to-moderate airway diseases. The vaccine is administered orally to stimulate mucosal-associated lymphoid tissue (MALT), leading to the induction of NTHi-specific T cells and IgG antibodies. This immune response aims to reduce the bacterial load of NTHi in the airways, thereby decreasing the frequency and severity of inflammatory episodes associated with NTHi colonization.
- Other names
- nontypeable Haemophilus influenzae strain 164 vaccineoral killed whole-cell NTHi vaccine
02
Targets
PRR (Pattern recognition receptors)Antigen-specific T-cell receptor recognizing non-typeable Haemophilus influenzae-derived peptides presented on MHC class II (NTHi-specific TCR)Antigen-specific B-cell receptor recognizing non-typeable Haemophilus influenzae surface antigen
Beyond the preview
Go deeper on HI-1-164.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HI-1-164.